Biotechnology company developing novel gene therapies for rare and genetically defined neurological diseases.
Astria Therapeutics, Inc. is a dynamic biopharmaceutical firm dedicated to advancing the discovery, development, and commercialization of therapeutic solutions tailored for rare and specialized allergic and immunological diseases within the United States. At the forefront of its pipeline is STAR-0215, a promising monoclonal antibody designed to inhibit plasma kallikrein, currently in the preclinical stages of development for treating hereditary angioedema, a rare genetic condition characterized by recurrent episodes of swelling in various parts of the body.
Formerly known as Catabasis Pharmaceuticals, Inc., the company rebranded as Astria Therapeutics, Inc. in September 2021, marking a strategic evolution in its mission and focus within the biopharmaceutical landscape. Established in 2008 and headquartered in Boston, Massachusetts, Astria Therapeutics operates at the forefront of scientific innovation, leveraging cutting-edge research to address unmet medical needs in niche disease areas.
Astria Therapeutics is committed to pioneering advancements that improve patient outcomes and quality of life through its targeted therapeutic approach. With a robust research and development strategy and a dedication to scientific excellence, the company continues to expand its portfolio of innovative treatments aimed at addressing complex and underserved medical conditions.
Driven by a vision to redefine treatment paradigms, Astria Therapeutics collaborates with key stakeholders in the healthcare community to accelerate the translation of scientific discoveries into transformative therapies. The company's strategic initiatives underscore its commitment to delivering meaningful advancements in the field of biopharmaceuticals.